Overview

A Safety, Tolerability and Preliminary Efficacy Study of BBI-02 Capsules in Healthy Subjects and Subjects With Atopic Dermatitis

Status:
Recruiting
Trial end date:
2023-10-01
Target enrollment:
Participant gender:
Summary
BBI-02 is an orally-available, potent and selective DYRK1A inhibitor.
Phase:
Phase 1
Details
Lead Sponsor:
Brickell Biotech, Inc.
Collaborators:
Innovaderm Research Inc.
Syneos Health